Lenalidomide Auxilia

Lenalidomide, the active ingredient in Lenalidomide Auxilia, is an immunomodulatory imide drug (IMiD) presented as a strength/form for oral use. It treats multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Auxilia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders.

- Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle Cell Lymphoma: contributes to disease control when combined with other therapies in relapsed settings.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Nausea: upset stomach often occurring after dosing. - Rash: mild skin eruptions or itching. - Constipation: reduced bowel movements causing discomfort. - Peripheral edema: swelling of extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil counts increasing infection risk. - Severe thrombocytopenia: low platelet counts leading to bleeding. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: elevated liver enzymes or liver injury.

Before initiating Lenalidomide therapy, several precautions should be considered. - Pregnancy risk: avoid use during pregnancy; ensure effective contraception. - Thromboembolic risk: assess need for prophylactic anticoagulation. - Renal function: adjust monitoring in patients with impaired kidney function. - Hematologic monitoring: perform regular blood counts to detect cytopenias. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25°C in original container, protect from moisture and light.

Lenalidomide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce plasma concentrations. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Immunosuppressants (e.g., cyclosporine): heightened risk of severe cytopenias.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors (e.g., verapamil): may increase exposure. - Vaccines (live attenuated): potential reduced efficacy or infection risk. - Hormonal contraceptives: possible decreased effectiveness.